Evidence map›Paper›PMID 39705875›Full record

Trial reportThe International journal on drug policy2025

Decrease in provider stigma is associated with improved quality health indicators among individuals receiving methadone in primary care centers in Ukraine.

Eteri Machavariani, Daniel J Bromberg, Kostyantyn Dumchev, Denise Esserman, Valerie A Earnshaw, Iryna Pykalo, Myroslava Filippovich, Roman Ivasiy, Bachar Ahmad, Jiang Long and 5 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The International journal on drug policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Eteri MachavarianiYale School of Medicine, Department of Medicine, Section of Infectious Diseases, New Haven, CT, United States; Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States. Electronic address: eteri.machavariani@yale.edu.
Daniel J BrombergCenter for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States; Yale School of Public Health, New Haven, CT, United States.
Kostyantyn DumchevUkrainian Institute of Public Health Policy, Kyiv, Ukraine.
Denise EssermanYale School of Public Health, New Haven, CT, United States.
Valerie A EarnshawDepartment of Human Development and Family Sciences, University of Delaware, Newark, DE, United States.
Iryna PykaloUkrainian Institute of Public Health Policy, Kyiv, Ukraine.
Myroslava FilippovichUkrainian Institute of Public Health Policy, Kyiv, Ukraine.
Roman IvasiyYale School of Medicine, Department of Medicine, Section of Infectious Diseases, New Haven, CT, United States; Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States.
Bachar AhmadYale School of Medicine, Department of Medicine, Section of Infectious Diseases, New Haven, CT, United States.
Jiang LongYale School of Medicine, Department of Medicine, Section of Infectious Diseases, New Haven, CT, United States; Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia; Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Marwan S HaddadCenter for Key Populations, Community Health Centers, Inc., Middletown, CT, United States.
Lynn M MaddenYale School of Medicine, Department of Medicine, Section of Infectious Diseases, New Haven, CT, United States; Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States; Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia; APT Foundation, Inc, New Haven, CT, United States.
David OliverosYale School of Medicine, Department of Medicine, Section of Infectious Diseases, New Haven, CT, United States; Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States.
Sergii DvoriakUkrainian Institute of Public Health Policy, Kyiv, Ukraine.
Frederick L AlticeYale School of Medicine, Department of Medicine, Section of Infectious Diseases, New Haven, CT, United States; Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States; Yale School of Public Health, New Haven, CT, United States; Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia; APT Foundation, Inc, New Haven, CT, United States.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
INTERDISCIPLINARY HIV PREVENTION TRAINING PROGRAMT32MH020031 · NIMH · YALE UNIVERSITY · PI Trace S Kershaw · 1999 to 2026
$12.1M
Integrating Addiction Treatment and HIV Services into Primary Care Clinics in UkraineR01DA043125 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2016 to 2021
$4.4M
Identifying Challenges and Opportunities for PrEP Uptake Among Women at Elevated HIV Risk in GeorgiaD43TW012492 · FIC · YALE UNIVERSITY · PI FREDERICK LEWIS ALTICE, Denise Esserman · 2023 to 2026
$1.3M
Developing, Implementing, and Pilot Testing an Informed Decision Aid for Opioid Agonist Therapies for Prisoners in UkraineF31DA054861 · NIDA · YALE UNIVERSITY · PI BROMBERG, DANIEL J · 2021 to 2023
$94k
FIC NIH HHS D43 TW010540FIC NIH HHS D43 TW012492NCATS NIH HHS UL1 TR001863NIDA NIH HHS F31 DA054861NIDA NIH HHS R01 DA043125NIMH NIH HHS T32 MH020031
6 · The paper itself

Abstract

introductionPeople who inject drugs experience poor health and social outcomes which improve with opioid agonist therapies like methadone, yet provider stigma may influence healthcare utilization. In Ukraine, integrating methadone into primary care centers (PCCs) provides an opportunity to examine provider stigma and its impact on patient outcomes.

methodsThis sub-analysis included patients randomized to receive methadone in PCCs as part of an implementation trial in which the control group received methadone in specialty addiction clinics in Ukraine. Methadone integration in PCCs was supported through continuous tele-education for providers. Provider stigma towards people who inject drugs, methadone, and attitudes towards evidence-based practices were assessed at baseline, 12, and 24 months using standardized scales (range 1-10). Patient-level outcomes were measured bi-annually over 24 months using a quality health indicator (QHI) score, a percentage of guideline-concordant primary and specialty health services accessed. Linear mixed-effects models examined the changes in provider stigma and attitudes, and the association of these measures with patient outcomes.

resultsThe sample included 583 patients and the 112 providers in 24 clinics. Provider fear and stereotypes toward people who inject drugs improved significantly, by 0.6 (95 % CI 0.2-1.1) and 0.4 points (95 % CI 0.1-0.8), respectively, as did preference for methadone over abstinence-based treatment (0.7 points, 95 % CI 0.2-1.1). A 1-point improvement in provider prejudice correlated with a 7.0-point increase (95 % CI: 1.1-13.0) in patient primary care QHI scores at 12 months, while improved attitudes towards evidence-based practices were associated with an 8.3-point increase (95 % CI: 1.1-13.0). Preference for methadone maintenance over abstinence was associated with a 3.7-point increase (95 % CI: 0.6-6.7) in specialty care QHI scores at 12 months, and reduced stereotypes were associated with a 10.9-point increase (95 % CI: 1.2-20.7) at 24 months.

conclusionsIntegrating methadone into PCCs with the support of provider tele-education may reduce provider stigma, particularly fear and stereotypes, toward people who inject drugs and methadone maintenance. Reducing provider stigma has the potential to improve patient outcomes through increased access to preventive care and screenings.

Indexed as

Attitude of Health PersonnelMethadoneOpiate Substitution TreatmentSocial StigmaSubstance Abuse, IntravenousAdultFemaleHumansMaleMiddle AgedOpioid-Related DisordersPrimary Health CareQuality Indicators, Health CareUkraineMethadoneHIVImplementation scienceIntegrated careMethadoneOpioid agonist therapies (OAT)People who inject drugs (PWID)Stigma

Identifiers

PMID39705875
PMCPMC11821433

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.